


This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (Currently amended) A compound of formula (I):



(I)

wherein

P<sup>1</sup> and P<sup>2</sup> independently represent ~~the residue of~~ a polyethylene glycol (PEG) ~~molecule moiety~~;

Z<sup>1</sup>, Z<sup>2</sup> and Z<sup>3</sup> independently represent ~~the residue of~~ a polyclonal, monoclonal, multi-valent, multi-specific, humanized or chimeric antibody, a single chain antibody, a Fab fragment, a Fab' or F(ab')<sub>2</sub> fragment, or an epitope-binding fragment thereof;

X<sup>1</sup>, X<sup>2</sup> and X<sup>3</sup> independently represent CR<sup>1</sup> or N;

A<sup>1</sup> and A<sup>2</sup> independently represent -CONH-, -NHCO-, -OC(O)N(R<sup>2</sup>)-, -N(R<sup>2</sup>)C(O)O- or -NHCONH-;

B<sup>1</sup>, B<sup>2</sup> and B<sup>3</sup> independently represent -CONH- or -CO-;

V<sup>1</sup>, V<sup>2</sup> and V<sup>3</sup> independently represent a covalent bond or -(CH<sub>2</sub>)<sub>v</sub>-;

W<sup>1</sup> and W<sup>2</sup> independently represent a covalent bond or -(CH<sub>2</sub>)<sub>w</sub>-;

Y<sup>1</sup>, Y<sup>2</sup> and Y<sup>3</sup> independently represent -(CH<sub>2</sub>)<sub>y</sub>-;

L<sup>1</sup>, L<sup>2</sup> and L<sup>3</sup> independently represent a maleimide ~~residue moiety~~;

M<sup>1</sup> and M<sup>2</sup> independently represent a covalent bond or -(CH<sub>2</sub>)<sub>m</sub>-;

R<sup>1</sup> represents hydrogen or C<sub>1-4</sub> alkyl;

R<sup>2</sup> represents hydrogen or C<sub>1-4</sub> alkyl;

n is zero, 1 or 2;

v is 1, 2, 3 or 4;


w is 1, 2, 3 or 4;

y is 1, 2, 3, 4, 5 or 6; and

m is 1, 2 or 3.

2. (Currently amended) A compound as claimed in claim 1 wherein  $Z^1$ ,  $Z^2$  and  $Z^3$  independently represent ~~the residue of~~ a whole antibody or ~~the residue of~~ a functionally active antibody fragment or derivative.

3. (withdrawn) A compound of formula (II):



(II)

wherein

$L^{11}$ ,  $L^{12}$  and  $L^{13}$  represent groups that attach residues  $Z^1$ ,  $Z^2$  and  $Z^3$ , respectively, or that are converted into groups that attach residues  $Z^1$ ,  $Z^2$  and  $Z^3$ , respectively;

$Z^1$ ,  $Z^2$  and  $Z^3$  independently represent the residue of a biologically active moiety;

$P^1$  and  $P^2$  independently represent a polymer residue;

$X^1$ ,  $X^2$  and  $X^3$  independently represent  $CR^1$  or N;

$A^1$  and  $A^2$  independently represent -CONH-, -NHCO-, -OC(O)N( $R^2$ )-, -N( $R^2$ )C(O)O- or -NHCONH-;

$B^1$ ,  $B^2$  and  $B^3$  independently represent -CONH- or -CO-;

$V^1$ ,  $V^2$  and  $V^3$  independently represent a covalent bond or  $-(CH_2)_v$ ;

$W^1$  and  $W^2$  independently represent a covalent bond or  $-(CH_2)_w$ ;

$Y^1$ ,  $Y^2$  and  $Y^3$  independently represent  $-(CH_2)_y$ ;

$M^1$  and  $M^2$  independently represent a covalent bond or  $-(CH_2)_m$ ;

$R^1$  represents hydrogen or  $C_{1-4}$  alkyl;

$R^2$  represents hydrogen or  $C_{1-4}$  alkyl;

n is zero, 1 or 2;


v is 1, 2, 3 or 4;

w is 1, 2, 3 or 4;

y is 1, 2, 3, 4, 5 or 6; and

m is 1, 2 or 3.

4. (withdrawn) A compound as claimed in claim 3 represented by formula (III):



5. (cancelled)

6. (withdrawn) A compound as claimed in claim 1 wherein  $R^1$  is hydrogen.

7. (previously presented) A compound as claimed in claim 1 wherein n is zero.

8. (previously presented) A compound as claimed in claim 1 that is

DiFab'-conjugated N,N'-bis-[4-maleimidylbutyl]-2,3-bis-(3-(methoxy-polyethoxy)-propionylamino)-succinamide;

DiFab'-conjugated 3-maleimidyl-N-(2-{[3-maleimidyl-propionyl]-[(2-(methoxy-polyethoxy)-ethylcarbamoyl)-methyl]-amino}-ethyl)-N-[(2-(methoxy-polyethoxy)-ethylcarbamoyl)-methyl]-propionamide; or

DiFab'-conjugated 3-maleimidyl-N-(2-{[3-(maleimidyl)-propionyl]-[2-(2-(methoxy-polyethoxy)-ethylcarbamoyl)-ethyl]-amino}-ethyl)-N-[2-(2-(methoxy-polyethoxy)-ethylcarbamoyl)-ethyl]-propionamide.

9. (withdrawn) A compound as claimed in claim 4 that is

N,N'-Bis-[4-maleimidylbutyl]-2,3-bis-(3-(methoxy-polyethoxy)-propionylamino)-succinamide;

3-Maleimidyl-N-(2-{[3-maleimidyl-propionyl]-[(2-(methoxy-polyethoxy)-ethylcarbamoyl)-methyl]-amino}-ethyl)-N-[(2-(methoxy-polyethoxy)-ethylcarbamoyl)-methyl]-propionamide; or

3-Maleimidyl-N-(2-{[3-(maleimidyl)-propionyl]-[2-(2-(methoxy-polyethoxy)-ethylcarbamoyl)-ethyl]-amino}-ethyl)-N-[2-(2-(methoxy-polyethoxy)-ethylcarbamoyl)-ethyl]-propionamide.

10. (previously presented) A pharmaceutical composition comprising a compound as claimed in claim 1 in association with one or more pharmaceutically acceptable carriers, excipients or diluents.